Stephen Blacklow
Directeur/Membre du Conseil chez Institute For Protein Innovation, Inc.
Provenance du réseau au premier degré de Stephen Blacklow
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
36
| Private Company | Investment Managers | 36 |
Institute For Protein Innovation, Inc.
 Institute For Protein Innovation, Inc. Miscellaneous Commercial ServicesCommercial Services Institute For Protein Innovation, Inc. is a non-profit company that focuses on enhancing the potential of recombinant antibodies. The company is based in Boston, MA. The company uses sophisticated yeast display technology to generate synthetic, recombinant antibodies. The company was founded by Andrew Kruse, Timothy A. Springer. Kenneth Fasman has been the CEO of the company since 2022.
11
| Non-Profit Organization | Miscellaneous Commercial Services | 11 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Stephen Blacklow via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Consultant / Advisor Director of Finance/CFO Private Equity Investor Private Equity Investor Private Equity Investor Consultant / Advisor Private Equity Investor Private Equity Investor Private Equity Investor Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree Masters Business Admin Doctorate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Corporate Officer/Principal Masters Business Admin Doctorate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree | |
| CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Director of Finance/CFO Director/Board Member | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member Chairman Director/Board Member Director/Board Member | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director of Finance/CFO President Chairman | |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Chairman Director/Board Member Director/Board Member Director/Board Member | |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member Director/Board Member | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member Founder | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder Director/Board Member | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder Director/Board Member | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| AVEO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| SCHOLAR ROCK HOLDING CORPORATION | Biotechnology | Founder Director/Board Member Director/Board Member | |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Chief Executive Officer | |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Medical/Nursing Services | Chairman Chief Executive Officer Corporate Officer/Principal | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Private Equity Investor | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Director/Board Member Director/Board Member | |
| CHIASMA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| OSS Healthcare, Inc. | Director/Board Member Director/Board Member | ||
KSQ Therapeutics, Inc.
 KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Founder | |
Rekindle Therapeutics, Inc.
 Rekindle Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rekindle Therapeutics, Inc. operates as an biotechnology company. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chairman Chief Executive Officer | |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Biotechnology | Corporate Officer/Principal Chief Operating Officer | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree | |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Medical Specialties | Director/Board Member Director/Board Member | |
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Mitobridge, Inc.
 Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman Founder | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| RHYTHM PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Founder | |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Director/Board Member | |
| REPARE THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Biotechnology | Founder Director/Board Member | |
| Georgetown University | College/University | Graduate Degree Undergraduate Degree | |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chief Executive Officer | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree Corporate Officer/Principal | |
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Biotechnology | Director/Board Member Founder | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Chief Executive Officer Private Equity Analyst |
Statistiques
Internationale
| Etats-Unis | 49 |
| Canada | 3 |
Sectorielle
| Health Technology | 31 |
| Finance | 8 |
| Consumer Services | 7 |
| Commercial Services | 4 |
| Health Services | 4 |
Opérationnelle
| Director/Board Member | 284 |
| Corporate Officer/Principal | 90 |
| Independent Dir/Board Member | 66 |
| Founder | 51 |
| Private Equity Investor | 47 |
Relations les plus connectées
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| Amir Nashat | 49 |
| Luke Evnin | 42 |
| Todd Foley | 38 |
| Thomas Ebeling | 33 |
| Edward Hurwitz | 27 |
| Briggs Morrison | 26 |
| Patrick Baeuerle | 19 |
| Elizabeth Stoner | 18 |
| Matt Roden | 18 |
| Timothy Springer | 17 |
| May Kin Ho | 16 |
| Joe Bolen | 14 |
| H. Robert Horvitz | 14 |
| Pankaj Bhargava | 13 |
- Bourse
- Insiders
- Stephen Blacklow
- Connexions Sociétés